REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

Alpha Fetoprotein ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00050-9 ◽

2015 ◽

Vol 16 (7) ◽

pp. 859-870 ◽

Cited By ~ 344

Author(s):

Andrew X Zhu ◽

Joon Oh Park ◽

Baek-Yeol Ryoo ◽

Chia-Jui Yen ◽

Ronnie Poon ◽

...

Keyword(s):

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

Line Therapy

P-285 A randomized, double-blind, placebo-controlled Phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)

Annals of Oncology ◽

10.1093/annonc/mdw199.275 ◽

2016 ◽

Vol 27 ◽

pp. ii83

Author(s):

Zhu Andrew ◽

Galle Peter ◽

Kudo Masatoshi ◽

Finn Richard ◽

Yang Ling ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps4145 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS4145-TPS4145

Author(s):

Andrew X. Zhu ◽

Peter R. Galle ◽

Masatoshi Kudo ◽

Richard S. Finn ◽

Ling Yang ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)

Annals of Oncology ◽

10.1093/annonc/mdw371.102 ◽

2016 ◽

Vol 27 ◽

pp. vi239 ◽

Cited By ~ 1

Author(s):

A.X. Zhu ◽

P.R. Galle ◽

M. Kudo ◽

R. Finn ◽

L. Yang ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Annals of Oncology ◽

10.1093/annonc/mdy208 ◽

2018 ◽

Vol 29 ◽

pp. v122 ◽

Cited By ~ 2

Author(s):

A. Zhu ◽

R. Finn ◽

P. Galle ◽

J. Llovet ◽

J F Blanc ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Line Treatment ◽

Second Line ◽

Efficacy And Safety ◽

First Line ◽

Phase 3

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.4077 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 4077-4077 ◽

Cited By ~ 1

Author(s):

Ian Chau ◽

Markus Peck-Radosavljevic ◽

Christophe Borg ◽

Peter Malfertheiner ◽

Jean Francois Seitz ◽

...

Keyword(s):

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Annals of Oncology ◽

10.1093/annonc/mdz154.020 ◽

2019 ◽

Vol 30 ◽

pp. iv133 ◽

Cited By ~ 1

Author(s):

T. Meyer ◽

R. Finn ◽

M. Kudo ◽

Y. Kang ◽

C. Yen ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Transarterial Chemoembolisation

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

European Journal of Cancer ◽

10.1016/s0959-8049(16)31253-9 ◽

2015 ◽

Vol 51 ◽

pp. S446

Author(s):

I. Chau ◽

J.O. Park ◽

B.Y. Ryoo ◽

C.J. Yen ◽

R. Poon ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Study Analysis ◽

First Line ◽

First Line Therapy ◽

Line Therapy

Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress

Annals of Oncology ◽

10.1093/annonc/mdy151.181 ◽

2018 ◽

Vol 29 ◽

pp. v51

Author(s):

S. Qin ◽

R. Finn ◽

M. Kudo ◽

T. Meyer ◽

A. Vogel ◽

...

Keyword(s):

Multicenter Study ◽

Study Trial ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Annals of Oncology ◽

10.1093/annonc/mdy282.006 ◽

2018 ◽

Vol 29 ◽

pp. viii208 ◽

Cited By ~ 4

Author(s):

A.X. Zhu ◽

R.S. Finn ◽

P.R. Galle ◽

J.M. Llovet ◽

J.F. Blanc ◽

...

Keyword(s):

Patient Reported Outcome ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Two Phase ◽

Patient Reported ◽

Phase Iii Studies